X

About this post

Source
Author
Date
10:39 PM | February 12, 2013
Language
English
Categories
URL
Link to this page


International Stem Cell Corporation (ISCC), a California based biomedical company, just announced via a press release positive preclinical results on their patented stem cell treatment for Criggler-Najjar syndrome type 1 (CN1). The study was conducted on a CN1 rodent model and it showed that the company's patented stem cell therapy is both efficient and safe. The press release fails to properly cite the study, so we redistribute the company's claims with caution.Full Story

Tags

Comments

Log in to leave a comment